---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-252474"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2026-06-02T11:05:07+00:00"
generated_at: "2026-06-02T11:12:43.447413+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Travere licenses Everest's BTK inhibitor with $112.5M upfront, up to $1.03B milestones

## Summary
- Exclusive license for civorebrutinib (BTK inhibitor) outside China and select East/Southeast Asia countries.
- Upfront payment of $112.5M; potential milestones up to ~$1.03B across up to five indications.
- Tiered royalties from high single-digit to double-digit percentages on net sales in Territory.
- Travere responsible for development and commercialization in Territory; global trial costs shared with Everest.
- Deal effective upon HSR clearance; Travere can terminate and get upfront refund if tech transfer fails.

## SEC filing metadata
- accession: 0001193125-26-252474
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2026-06-02T11:05:07+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000119312526252474/0001193125-26-252474-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000119312526252474/d107618d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-252474
- JSON: https://secwatch.observer/filing/0001193125-26-252474.json
- Plain text: https://secwatch.observer/filing/0001193125-26-252474.txt

## Source-grounded claims
- claim_id: ecdfbac9c8e9c51a3587fb05d5ca9d2031e7275b
  claim: Travere Therapeutics, Inc. entered into Agreement with Everest Medicines (Singapore) Pte. Ltd. valued at upfront payment of $112.5 million (effective 2026-06-01).
  evidence_excerpt: On June 1, 2026, Travere Therapeutics, Inc. (the “Company”) entered into a license and collaboration agreement (the “Agreement”) with Everest Medicines (Singapore) Pte. Ltd. (“Everest”), pursuant to which Everest grants an exclusive license to the Company for the development and commercialization of civorebrutinib
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000119312526252474/0001193125-26-252474-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.